The Apex Times
Above the Noise
Business Wire
BusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex TimesBusinessUPS says its reorganization will lean more heavily on global logistics than domestic parcel operationsThe Apex TimesBusinessGeneral Dynamics shares fall more than the broader market in late-session tradingThe Apex TimesBusinessEli Lilly to buy Merdia Biosciences in a deal valued at up to $2.88 billion, indicating renewed focus on pipeline expansionThe Apex TimesBusinessNvidia hardware momentum meets a new choke point: copper, not cash, HIVE Digital’s Frank Holmes saysThe Apex TimesBusinessBroadcom’s Sept. 2 earnings set up a high-stakes test for its AI narrativeThe Apex TimesBusinessPalantir CEO Alex Karp pushes back on “tokenmaxxing,” pitching real-world AI value over hypeThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging inflated prices in online ads schemeThe Apex TimesBusinessTesla shares rise after investors refocus on long-term autonomous driving potentialThe Apex TimesBusinessTim Cook’s final day as Apple CEO caps a 15-year push into services, wearables and paymentsThe Apex TimesBusinessNetflix announces new original comedy led by Camila Pitanga and Sergio GuizéThe Apex TimesBusinessWall Street stays upbeat on GE Aerospace after the shares outpace the NasdaqThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex TimesBusinessUPS says its reorganization will lean more heavily on global logistics than domestic parcel operationsThe Apex TimesBusinessGeneral Dynamics shares fall more than the broader market in late-session tradingThe Apex TimesBusinessEli Lilly to buy Merdia Biosciences in a deal valued at up to $2.88 billion, indicating renewed focus on pipeline expansionThe Apex TimesBusinessNvidia hardware momentum meets a new choke point: copper, not cash, HIVE Digital’s Frank Holmes saysThe Apex TimesBusinessBroadcom’s Sept. 2 earnings set up a high-stakes test for its AI narrativeThe Apex TimesBusinessPalantir CEO Alex Karp pushes back on “tokenmaxxing,” pitching real-world AI value over hypeThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging inflated prices in online ads schemeThe Apex TimesBusinessTesla shares rise after investors refocus on long-term autonomous driving potentialThe Apex TimesBusinessTim Cook’s final day as Apple CEO caps a 15-year push into services, wearables and paymentsThe Apex TimesBusinessNetflix announces new original comedy led by Camila Pitanga and Sergio GuizéThe Apex TimesBusinessWall Street stays upbeat on GE Aerospace after the shares outpace the NasdaqThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex TimesBusinessUPS says its reorganization will lean more heavily on global logistics than domestic parcel operationsThe Apex TimesBusinessGeneral Dynamics shares fall more than the broader market in late-session tradingThe Apex TimesBusinessEli Lilly to buy Merdia Biosciences in a deal valued at up to $2.88 billion, indicating renewed focus on pipeline expansionThe Apex TimesBusinessNvidia hardware momentum meets a new choke point: copper, not cash, HIVE Digital’s Frank Holmes saysThe Apex TimesBusinessBroadcom’s Sept. 2 earnings set up a high-stakes test for its AI narrativeThe Apex TimesBusinessPalantir CEO Alex Karp pushes back on “tokenmaxxing,” pitching real-world AI value over hypeThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging inflated prices in online ads schemeThe Apex TimesBusinessTesla shares rise after investors refocus on long-term autonomous driving potentialThe Apex TimesBusinessTim Cook’s final day as Apple CEO caps a 15-year push into services, wearables and paymentsThe Apex TimesBusinessNetflix announces new original comedy led by Camila Pitanga and Sergio GuizéThe Apex TimesBusinessWall Street stays upbeat on GE Aerospace after the shares outpace the NasdaqThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex TimesBusinessUPS says its reorganization will lean more heavily on global logistics than domestic parcel operationsThe Apex TimesBusinessGeneral Dynamics shares fall more than the broader market in late-session tradingThe Apex TimesBusinessEli Lilly to buy Merdia Biosciences in a deal valued at up to $2.88 billion, indicating renewed focus on pipeline expansionThe Apex TimesBusinessNvidia hardware momentum meets a new choke point: copper, not cash, HIVE Digital’s Frank Holmes saysThe Apex TimesBusinessBroadcom’s Sept. 2 earnings set up a high-stakes test for its AI narrativeThe Apex TimesBusinessPalantir CEO Alex Karp pushes back on “tokenmaxxing,” pitching real-world AI value over hypeThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging inflated prices in online ads schemeThe Apex TimesBusinessTesla shares rise after investors refocus on long-term autonomous driving potentialThe Apex TimesBusinessTim Cook’s final day as Apple CEO caps a 15-year push into services, wearables and paymentsThe Apex TimesBusinessNetflix announces new original comedy led by Camila Pitanga and Sergio GuizéThe Apex TimesBusinessWall Street stays upbeat on GE Aerospace after the shares outpace the NasdaqThe Apex Times
Back to front
Pfizer’s berobenatide data sharpen the pitch for monthly GLP-1 obesity dosing
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jun 7, 1:22 AM EDT

Pfizer’s berobenatide data sharpen the pitch for monthly GLP-1 obesity dosing

At the American Diabetes Association meeting, Pfizer highlighted Phase 2b results for PF’3944 (berobenatide), an ultra-long-acting GLP-1 receptor agonist designed for once-monthly maintenance dosing - along with early tolerability outlines that will shape how investors weigh Pfizer’s obesity push.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Pfizer used a late-breaking presentation at the American Diabetes Association’s 86th Scientific Sessions to lay out detailed Phase 2b findings for berobenatide (PF’3944), an investigational GLP-1 receptor agonist being developed as both a once-weekly and once-monthly injectable for adults with obesity or overweight. The company positioned the program’s core concept as proof that weight loss can continue after a planned shift from weekly dosing to monthly maintenance. MarketScreener

In VESPER-3, Pfizer described a regimen intended to “titrate” on weekly dosing before transitioning to higher monthly doses: participants received weekly berobenatide injections until week 12, then moved to monthly subcutaneous dosing through week 28. The study is randomized, double-blind, placebo-controlled, and is ongoing through 64 weeks, with multiple dose arms compared with placebo. Pfizer press release

On efficacy, Pfizer reported that the primary endpoint - weight reduction from randomization to week 28 - was superior to placebo across four dose regimens tested (P<0.001). It said mean placebo-adjusted weight loss reached up to 12.3% at week 28, and that weight loss continued after the pre-planned switch from weekly to monthly dosing, with no plateau observed by that time point. Pfizer press release

Tolerability was a second focus of the June 6 presentation, particularly as Pfizer tries to differentiate a monthly GLP-1 option in a market dominated by weekly injections. Reuters, citing Pfizer’s meeting presentation, reported that mean nausea across VESPER-3 arms was around 38% and mean vomiting was about 23.3%, and that Pfizer executives described side effects as “front-loaded” around dosing rather than persisting uniformly through the month. PM360 (Reuters)

Beyond the data itself, the company framed the results as stepping-stones toward a broader Phase 3 plan. Pfizer said it expects 10 Phase 3 trials of PF’3944 to advance in 2026, including VESPER-4 (once-weekly in people without type 2 diabetes), VESPER-5 (once-weekly in people with type 2 diabetes), and VESPER-6 (once-monthly maintenance). The implication for the investment case is that investors will now look to whether Pfizer can carry efficacy and tolerability into pivotal studies with longer follow-up. Pfizer press release

Even with the promising week-28 announcement and the “no plateau” message after switching to monthly dosing, observers will likely be waiting for data that clarifies competitive positioning and durability. STAT reported that while the meeting presentation offered further evidence that berobenatide can be dosed monthly, it was not yet clear how competitive it would be versus existing weekly injectables, and the discussion of week-28 results leaves room for uncertainty about relative magnitude versus leaders in late-stage trials. STAT

Why It Matters

  • Monthly dosing could be an important differentiator in obesity care if it helps adherence and consumer preference versus weekly injections, but Pfizer will still need pivotal data to prove it can match outcomes at scale.
  • The week-28 “no plateau” message supports the biological plausibility of sustained weight loss after switching to monthly maintenance, yet longer-term durability will be the next key proof point.
  • Tolerability remains a central variable for whether monthly GLP-1 strategies can become commercially viable; the Reuters-reported nausea/vomiting rates set the bar for future trial readouts.
  • Investors and competitors are likely to focus on how PF’3944’s efficacy and side-effect profile compare with late-stage results from established weekly obesity drugs as Phase 3 timelines unfold.

Sources

Key Facts

  • Pfizer presented detailed Phase 2b results for berobenatide (PF’3944), an investigational GLP-1 receptor agonist developed for once-weekly and once-monthly dosing.
  • In VESPER-3, participants took weekly berobenatide for 12 weeks before switching to monthly dosing through week 28; the study runs for 64 weeks and includes placebo control.
  • Pfizer reported the VESPER-3 primary endpoint (weight change from randomization to week 28) was statistically significant versus placebo across four dose regimens (P<0.001).
  • Placebo-adjusted mean weight loss in VESPER-3 was reported as up to 12.3% at week 28.
  • Pfizer said weight loss continued after the weekly-to-monthly switch and that no plateau was observed at week 28.
  • Reuters reported Pfizer meeting data indicating mean nausea around 38% and mean vomiting around 23.3% in VESPER-3, with side effects described as clustered around dosing rather than persisting through the month.
  • Pfizer said it plans to advance 10 Phase 3 trials for PF’3944 in 2026, including a once-monthly maintenance study (VESPER-6).

Healthcare Related

Pfizer’s berobenatide data sharpen the pitch for monthly GLP-1 obesity dosing | The Apex Times